Work | Tumor Initiating Cells
Development Program for Neuroblastoma-specific Oncolytic Virus
Identification of the Optimal Virus Therapeutic for Neuroblastoma
The objective of this proof of concept study is to create a new oncolytic virus that specifically attacks neuroblastoma. The first step will be to screen all available oncolytic viruses and evaluate them based on their ability to infect and selectively eradicate neuroblastoma cells. The most viable viruses will be subjected to in vitro and in vivo testing to determine if their tumor-killing properties can be enhanced to make the virus more selective and potent against neuroblastoma. This end-product will be evaluated in a Phase I Clinical Trial.
The program focuses on initial screening efforts using already available viruses, including Vaccinia, Rhabdovirus and Semliki Forest Virus backbones. The samples will be tested on established neuroblastoma cell lines and tumor initiating cells (TICs) from the David Kaplan collection.
Therapeutic Development Project Links
- Nifurtimox Phase I Clinical Trial
- Nifurtimox Phase II Clinical Trial
- Neuroblastoma Drug Discovery Program
- Rapamycin + Vinblastine Phase I Study
- Patient-specific Therapeutic Development for Neuroblastoma
- Oncolytic Virus Program
- Development Program for Neuroblastoma-specific Oncolytic Virus
- Natural Killer Cell Transplant Pilot Study
- Phase I Clinical Trial of HSV Oncolytic Virus